<p>Myeloproliferative neoplasms (MPNs) are clonal stem cell diseases that, under the World Health Organization classification, are subcategorized into eight clinicopathologic entities. The current book focuses on three of these categories: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. A number of important questions regarding the diagnosis, prognosis, and treatment of these diseases have arisen following the discovery of the <i>JAK2</i> V617F mutation in the majority of patients with <i>bcr</i>/<i>abl</i>-negative MPNs. </p><p> </p><p>This book comprises evidence-based reviews and expert consensus results. It offers comprehensive coverage of relevant laboratory and clinical advances and places great emphasis on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic  approaches, the value and limitations of mutation screening for diagnostic and  prognostic purposes, risk stratification in terms of both survival and other  disease complications such as leukemic transformation and thrombosis, and  modern therapeutic strategies, including conventional drugs, allogeneic stem cell  transplantation, and experimental drugs still under study. The reader will find <i>Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms</i> to be an invaluable and up-to-date source of information from leading authorities in the field.</p>